DCLK1 and colorectal carcinoma: Among eleven reports on in vivo studies, three studies highlighted the oncogenic and therapeutic function of DCLK1 using DCLK1-L antibodies [20, 47, 48], five used anti-DCLK1-L/S antibodies [11, 44, 49–51], and only one study used specific anti-DCLK1-S antibodies [34] in CRC.